A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Study Summary

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

Conditions

Systemic Sclerosis Idiopathic Inflammatory Myopathies Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions / Drugs

NKX019 Fludarabine Cyclophosphamide

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment144 participants

Primary Completion—

Lead SponsorNkarta, Inc.

Data Retrieved2026-04-11 04:22:44.430417+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.